Literature DB >> 7684551

Effect of growth hormone treatment on hormonal parameters, body composition and strength in athletes.

R Deyssig1, H Frisch, W F Blum, T Waldhör.   

Abstract

The effect of recombinant GH on strength, body composition and endocrine parameters in power athletes was investigated in a controlled study. Twenty-two healthy, non-obese males (age 23.4 +/- 0.5 years; ideal body weight 122 +/- 3.1%, body fat 10.1 +/- 1.0%; mean +/- SEM) were included. Probands were assigned in a double-blind manner to either GH treatment (0.09U (kg BW)-1 day-1 sc) or placebo for a period of six weeks. To exclude concurrent treatment with androgenic-anabolic steroids urine specimens were tested at regular intervals for these substances. Serum was assayed for GH, IGF-I, IGF-binding proteins, insulin and thyroxine before the onset of the study and at two-weekly intervals thereafter. Maximal voluntary strength of the biceps and quadriceps muscles was measured on a strength training apparatus. Fat mass and lean body mass were derived from measurements of skinfolds at ten sites with a caliper. For final evaluation only data of those 8 and 10 subjects in the two groups who completed the study were analyzed. GH, IGF-I and IGF-binding protein were in the normal range before therapy and increased significantly in the GH-treated group. Fasting insulin concentrations increased insignificantly and thyroxine levels decreased significantly in the GH-treated probands. There was no effect of GH treatment on maximal strength during concentric contraction of the biceps and quadriceps muscles. Body weight and body fat were not changed significantly during treatment. We conclude that the anabolic, lipolytic effect of GH therapy in adults depends on the degree of fat mass and GH deficiency.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7684551     DOI: 10.1530/acta.0.1280313

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  19 in total

Review 1.  Athletes and doping: effects of drugs on the respiratory system.

Authors:  P N Dekhuijzen; H A Machiels; L M Heunks; H F van der Heijden; R H van Balkom
Journal:  Thorax       Date:  1999-11       Impact factor: 9.139

2.  Problems with GH doping in sports.

Authors:  M Bidlingmaier; Z Wu; C J Strasburger
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

Review 3.  Interactions of metabolic hormones, adipose tissue and exercise.

Authors:  Robert G McMurray; Anthony C Hackney
Journal:  Sports Med       Date:  2005       Impact factor: 11.136

Review 4.  Performance-enhancing substances in sports: a review of the literature.

Authors:  Amit Momaya; Marc Fawal; Reed Estes
Journal:  Sports Med       Date:  2015-04       Impact factor: 11.136

Review 5.  Human growth hormone doping in sport.

Authors:  M Saugy; N Robinson; C Saudan; N Baume; L Avois; P Mangin
Journal:  Br J Sports Med       Date:  2006-07       Impact factor: 13.800

6.  Recombinant human growth hormone treatment at low doses does not significantly change thyroid function in growth hormone deficient adults.

Authors:  G Amato; G Izzo; I Salzano; A Bellastella
Journal:  J Endocrinol Invest       Date:  1996-09       Impact factor: 4.256

Review 7.  Drugs and sport. Research findings and limitations.

Authors:  P M Clarkson; H S Thompson
Journal:  Sports Med       Date:  1997-12       Impact factor: 11.136

8.  Risk of Creutzfeldt-Jakob disease in bodybuilders.

Authors:  H M Perry
Journal:  BMJ       Date:  1993-09-25

9.  Growth hormone abuse and bodybuilding as aetiological factors in the development of bilateral internal laryngocoeles. A case report.

Authors:  James W Moor; M Iqbal J Khan
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-03-02       Impact factor: 2.503

Review 10.  Modulation of GH/IGF-1 axis: potential strategies to counteract sarcopenia in older adults.

Authors:  Silvia Giovannini; Emanuele Marzetti; Stephen E Borst; Christiaan Leeuwenburgh
Journal:  Mech Ageing Dev       Date:  2008-08-13       Impact factor: 5.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.